Company Overview of Hospira Inc.
Hospira, Inc. provides injectable drugs and infusion technologies to develop, manufacture, distribute, and market products worldwide. The company operates through Americas, EMEA, and APAC segments. It provides specialty injectable pharmaceuticals, which include approximately 200 injectable generic drugs in multiple dosages and formulations; and proprietary specialty injectables, such as Precedex, a proprietary drug for sedation. The company’s specialty injectable pharmaceuticals also comprise Biosimilars that include Retacrit, an EPO, which is primarily used in the treatment of anemia in dialysis and in certain oncology applications; Nivestim, a biosimilar filgrastim used for the treatment o...
275 North Field Drive
Lake Forest, IL 60045
Founded in 2003
Key Executives for Hospira Inc.
Chief Financial Officer and Senior Vice President of Finance
Senior Vice President of Operations
President of Hospira Medical Devices
President of US Operations
Chief Scientific Officer and Senior Vice President
Compensation as of Fiscal Year 2017.
Hospira Inc. Key Developments
Sheridan Memorial Hospital Implements Interoperable Alarm Technology Between Cerner and Hospira
Dec 14 16
Cerner and Hospira have announced that Sheridan Memorial Hospital in Sheridan, Wyoming, is the first hospital to integrate Cerner’s CareAware Event Management™ secondary alerting solution with Hospira infusion system Alarm Forwarding technology. CareAware Event Management is designed to route alerts from medical devices or nurse call systems to a clinician’s mobile device. With this implementation, Sheridan expanded its infusion alarm management functionality. Within the hospital, clinicians can receive alarm information from Hospira’s Plum A+™ infusion system through CareAware Event Management. The new technology also provides a system to escalate alerts among clinicians when assistance is needed or a primary caregiver is not available. The secondary Cerner alert, enabled by Hospira MedNet™ v6.1 next-generation safety software, is designed to help Sheridan clinicians respond more quickly and appropriately to smart pump alarms by automating the delivery of alarm data. Clinicians can now receive secondary alerts remotely and still be able to identify the specific device, patient and alarm type involved. In addition to Plum A+, Hospira MedNet supports Alarm Forwarding capability for Hospira Plum 360™ and LifeCare PCA® 7.0 infusion systems.
Pfenex Inc. Terminates Agreement with Hospira Inc
Aug 8 16
On February 9, 2015, Pfenex Inc. (the Company) and Hospira Inc. (together with its affiliates, Pfizer), entered into a Development and License Agreement (the Collaboration Agreement) pursuant to which the Company and Pfizer agreed to collaboratively develop the Company's biosimilar candidate to Lucentis, PF582 (the Product) for retinal conditions. Under the terms of the Collaboration Agreement, Pfizer received exclusive licenses and rights and assumed responsibility for the sale, marketing, promotion and commercialization of the Product, and was obligated to use commercially reasonable efforts to sell, market, promote and commercialize the Product in certain named major markets. In consideration for the exclusive license and other rights contained in the Collaboration Agreement, the Company was eligible to receive up to $342 million in one-time payments, including $51 million that was received once the Collaboration Agreement received U.S. antitrust approval, up to $291 million upon the successful achievement of certain pre-commercial and commercial milestones, and double digit escalating royalties on annual sales of the Product. Pfenex will regain the full rights to PF582 following Pfizer's strategic review of the current therapeutic focus of its biosimilar pipeline. To that effect, on August 5, 2016, the Company, Hospira Bahamas Biologics Ltd., and Hospira Inc., entered into a Termination Agreement (the Termination Agreement) pursuant to which the parties agreed to terminate the Collaboration Agreement. Such termination of the Collaboration Agreement was effective as of August 5, 2016 (the Termination Date). Under the terms of the Termination Agreement, the Company regained exclusive, worldwide rights for, and the parties terminated their collaboration in regard to, the development, manufacture and commercialization of the Product. The Termination Agreement further provides for the grant by Pfizer to the Company of a perpetual license under intellectual property rights developed by Pfizer under the Collaboration Agreement, the transfer from Pfizer to the Company of know-how and regulatory materials relating to the Product that were generated by Pfizer under the Collaboration Agreement, and the formation of a transition committee with equal representation to establish and oversee the implementation of a transition plan. In addition, the Termination Agreement provides for a mutual release of claims and restricts Pfizer and its affiliates from developing or commercializing a competing product (in relation to the Product) during the period of 12 months following the Termination Date.
Teva Pharmaceutical Industries Ltd. Announces Favorable Court Ruling in TREANDA Patent Infringement Litigation Against Hetero Usa, Inc., Innopharma Inc., Hospira Inc., Sagent Pharmaceuticals Inc., and Accord Healthcare Inc
Jun 10 16
Teva Pharmaceutical Industries Ltd. announced that the United States District Court for the District of Delaware has ruled in favor of Teva in the Company’s patent infringement lawsuit against Hetero USA, Inc., InnoPharma Inc., Hospira Inc., Sagent Pharmaceuticals Inc., and Accord Healthcare Inc., regarding Teva’s TREANDA (bendamustine hydrochloride) for Injection. At trial, the defendants alleged that certain claims of U.S. Patents 8,436,190; 8,609,863; 8,791,270; and 8,895,756, listed in the Orange Book for TREANDA®, are invalid. The defendants had previously stipulated to infringement of certain claims of these patents.
Similar Private Companies By Industry
Recent Private Companies Transactions